» Articles » PMID: 7702047

Focal Segmental Glomerular Sclerosis in Adults: Presentation, Course, and Response to Treatment

Overview
Journal Am J Kidney Dis
Specialty Nephrology
Date 1995 Apr 1
PMID 7702047
Citations 69
Authors
Affiliations
Soon will be listed here.
Abstract

The authors performed a retrospective clinicopathologic study in 81 patients with primary focal segmental glomerular sclerosis (FSGS) to determine whether they could identify clinical or histologic features at presentation that could be predictive of outcome and response to therapy. Males constituted 58% of patients, and 53% were black. At biopsy the patients were 40 +/- 17 years old; 74% were nephrotic, and renal insufficiency was present in 62%. The average time from presentation to biopsy was 16 months, and the average total follow-up was 62 months. Nephrotic patients had a significantly poorer prognosis as compared with nonnephrotic patients (5- and 10-year survivals of 76% and 57% v 92% and 92%; P < 0.05). A multivariate analysis was done on histologic and clinical features at biopsy, assessing for risk factors leading to end-stage renal disease, showing only the serum creatinine and the degree of interstitial fibrosis to have a significant correlation. Thirty nephrotic patients received prednisone, with a treatment time of 5.5 +/- 4 months and a total dose of 5.9 +/- 2.9 g per course of treatment. Fifteen of these patients (50%) achieved a remission by 3.7 +/- 2 months (10 complete remission and 5 partial remissions), with all patients responding within 9 months. Only two patients had spontaneous remissions (both partial). The 5- and 10-year survival for patients in remission were both 100% as compared with 66% and 41% (P < 0.01), respectively, for nephrotic patients not in remission. No clinical feature at presentation of biopsy was predictive of response to therapy when a multivariate analysis was performed.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Nephrotic and Non-Nephrotic Focal Segmental Glomerulosclerosis: Clinical Characteristics, Etiology, and Columbia Classification.

Figueiredo G, Yu L, Jorge L, Woronik V, Dias C Diagnostics (Basel). 2025; 15(2).

PMID: 39857004 PMC: 11763650. DOI: 10.3390/diagnostics15020120.


Pathogenesis of Focal Segmental Glomerulosclerosis and Related Disorders.

Altintas M, Agarwal S, Sudhini Y, Zhu K, Wei C, Reiser J Annu Rev Pathol. 2025; 20(1):329-353.

PMID: 39854184 PMC: 11875227. DOI: 10.1146/annurev-pathol-051220-092001.


Renal survival and treatment of adult patients with Primary Focal Segmental glomerulosclerosis: A historical cohort study of the National Greek Registry.

Marinaki S, Kompotiatis P, Michelakis I, Stangou M, Papagianni A, Koukoulaki M PLoS One. 2024; 19(12):e0315124.

PMID: 39693288 PMC: 11654980. DOI: 10.1371/journal.pone.0315124.


A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING).

C Willcocks L, Qian W, Cader R, Gatley K, Siddiqui H, Tabebisong E BMC Nephrol. 2024; 25(1):253.

PMID: 39112932 PMC: 11308314. DOI: 10.1186/s12882-024-03576-0.


Long-term outcomes of adults with FSGS in the German Chronic Kidney Disease cohort.

Stamellou E, Nadal J, Hendry B, Mercer A, Bechtel-Walz W, Schiffer M Clin Kidney J. 2024; 17(7):sfae131.

PMID: 38989280 PMC: 11234294. DOI: 10.1093/ckj/sfae131.